Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04034459
Other study ID # FIRE-4.5
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 25, 2016
Est. completion date December 31, 2023

Study information

Verified date November 2023
Source Ludwig-Maximilians - University of Munich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Once randomisation has been completed, the study treatment should be started preferably immediately; at the latest within one week following randomisation. The patients will be randomised in a ratio of 1:2 to the following two treatment arms. Patients in both treatment arms will receive standard chemotherapy with FOLFOXIRI as background treatment, which can be de-escalated to FOLFIRI in case of toxicity. Standard arm A: The patient will be treated with FOLFOXIRI plus bevacizumab for up to 12 cycles (24 weeks) or until progression (if the latter occurs before completing the 12 cycles). Within the 12 cycles, the FOLFOXIRI plus bevacizumab regimen may be de-escalated, owing to toxicity, to FOLFIRI and bevacizumab at the treating physician's discretion. After 12 cycles of the study treatment, a switch to a maintenance regimen with a fluoropyrimidine (5-FU infusion or capecitabine) plus bevacizumab, administered until progression occurs, is recommended. The recommended maintenance phase of the study is not part of the study treatment. However, maintenance therapy will be counted as first-line therapy. Experimental arm B: The patient will be treated with FOLFOXIRI plus weekly administration of cetuximab for up to 12 cycles (24 weeks) or until progression (if the latter occurs before completing the 12 cycles). Within the 12 cycles, the FOLFOXIRI plus cetuximab regimen may be de-escalated owing to toxicity, to FOLFIRI and cetuximab at the treating physician's discretion. After 12 cycles, a switch to a maintenance regimen with 5-FU and cetuximab or with irinotecan and cetuximab, administered until progression occurs, is recommended. The recommended maintenance phase of the study is not part of the study treatment. However, maintenance therapy will be counted as first-line therapy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 109
Est. completion date December 31, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed UICC stage IV adenocarcinoma of the colon or rectum with metastases (metastatic colorectal cancer [mCRC]); metastases primarily non-resectable or surgery refused by the patient - RAS wild-type tumour status (KRAS and NRAS exons 2, 3, 4) (proven in the primary tumour or metastasis) - BRAF-mutant (V600E) tumour (proven in the primary tumour or metastasis) - Age =18 years - ECOG performance status 0-1 - Patients suitable for chemotherapy administration - Patient's written declaration of consent obtained - Estimated life expectancy > 3 months - Presence of at least one measurable lesion according to the RECIST 1.1 - criteria (chest X-ray in two planes or chest CT and abdominal CT 4 weeks or less before randomisation) - Primary tumour tissue available and patient consents to storage and molecular and genetic profiling of the tumour material. Molecular profiling of blood samples is optionally performed. - Females of childbearing potential (FCBP) and men must agree to use effective contraceptive measures (Pearl index <1) for the duration of the study treatment and for at least 6 months after last administration of the study medication. A female subject will be considered to be of child-bearing potential unless she is = 50 years of age as well as has had a natural menopause for at least 2 years or has been surgically sterilised. - Adequate bone marrow function: - Leukocytes = 3.0 x 109/L with neutrophils = 1.5 x 109/L - Thrombocytes = 100 x 109/L, - Haemoglobin = 5.6 mmol/L (equivalent to 9 g/dL) - Adequate hepatic function: - Serum bilirubin = 1.5 x upper limit of normal (ULN), - ALAT and ASAT = 2.5 x ULN (in case of hepatic metastasis, ALAT and ASAT = 5 x ULN) - INR < 1.5 and aPTT < 1.5 x ULN (patients without anticoagulation). Therapeutic anticoagulation is allowed if INR and aPTT have remained stable within the therapeutic range for at least 2 weeks. - Adequate renal function: - Serum creatinine = 1.5 x ULN or creatinine clearance (calculated according to Cockcroft and Gault) = 50mL/min. - Adequate cardiac function: ECG and echocardiogram with a LVEF of = 55% - No previous chemotherapy for metastatic disease (prior radiotherapy of metastasis/metastases without application of chemotherapy permitted provided that no irradiated metastasis is selected as target lesion) - Time interval since last administration of any previous neoadjuvant/adjuvant chemotherapy or radiochemotherapy =6 months - Any relevant toxicities of previous treatments must have subsided to grade 0 Exclusion Criteria: - Grade III or IV heart failure (NYHA classification) - Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before randomisation - Pregnancy (absence of pregnancy has to be ascertained by a beta hCG test) or breast feeding - Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study - Additional cancer treatment (chemotherapy, radiation, immune therapy or hormone treatment) during the study treatment. Treatments that are conducted as part of an anthroposophical or homeopathic treatment approach, e.g. mistletoe therapy, do not represent an exclusion criterion. - Previous chemotherapy for the colorectal cancer with exception of chemotherapy or radiochemotherapy given as neoadjuvant or adjuvant treatment with curative intent, completed =6 months before entering the study. - Participation in a clinical study or experimental drug treatment within 30 days prior to study inclusion or within a period of 5 half-lives of the substances administered in a clinical study or during an experimental drug treatment prior to inclusion in the study, depending on which period is longest, or simultaneous participation in another clinical study while taking part in the study - Known hypersensitivity or allergic reaction to any of the following substances: 5-fluorouracil, folinic acid, cetuximab, irinotecan, bevacizumab, oxaliplatin and chemically related substances and/or hypersensitivity to any of the excipients of any of the aforementioned substances - Known hypersensitivity to CHO (Chinese hamster ovary cells) - cell products or other recombinant human or humanised antibodies - Patients with confirmed cerebral metastases. In case of clinical suspicion of brain metastases, a cranial CT or MRI must be performed to rule out brain metastases before study inclusion. - History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea. - Symptomatic peritoneal carcinosis - Severe, non-healing wounds, ulcers or bone fractures - Patients with active infection (including confirmed HIV and/or HBV/HCV infection). In case of clinical suspicion of the presence of HIV or HBV/HCV infection, the latter should be ruled out before study inclusion. - Requirement for immunisation with live vaccine during the study treatment. - Uncontrolled hypertension - Marked proteinuria (nephrotic syndrome) - Arterial thromboembolism or severe haemorrhage within 6 months prior to randomisation (with the exception of tumour bleeding before tumour resection surgery) - Haemorrhagic diathesis or tendency towards thrombosis - Known DPD deficiency (specific screening not required) - Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not required) - History of a second malignancy during the 5 years before inclusion in the study or during participation in the study, with the exception of a basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, if these were treated curatively. - Known history of alcohol or drug abuse - A significant concomitant disease, in particular chronic hepatic or renal disease, chronic inflammatory or autoimmune diseases, ruling out the patient's participation in the study according to investigator's judgement. - Absent or restricted legal capacity

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bevacizumab
Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1
Irinotecan
Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
Folinic acid
Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
Oxaliplatin
Oxaliplatin 85mg/m² day 1
5-FU
5-FU 3000 mg/m² iv over 48 h days 1-2
Cetuximab
Cetuximab initially 400 mg/m² with infusion rate of =5 mg/min., subsequently 250 mg/m² iv with infusion rate of =10 mg/min. days 1+8

Locations

Country Name City State
Germany Klinikum der Universitaet Muenchen Munich

Sponsors (1)

Lead Sponsor Collaborator
Ludwig-Maximilians - University of Munich

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate (ORR) (overall response rate) measured in percentage of all treated patients according to RECIST 1.1 criteria up to 48 months
Secondary Progression Free Survival (PFS) Investigation of progression-free survival (PFS) from randomisation up to 60 months
Secondary Overall Survival (OS) Investigation of overall survival (OS) from randomisation up to 60 months
Secondary Investigation of Early Tumour Shrinkage (ETS) as early-on-Treatment predictor for treatment Investigation of early tumour shrinkage (ETS) up to 48 months
Secondary Investigation of Depth of Response (DpR) to define nadir for tumour response. Investigation of depth of response (DpR) up to 48 months
Secondary Investigation of Molecular Biomarkers for Prediction of an Anti-EGFR Treatment Investigation of molecular biomarkers for prediction of sensitivity and secondary resistance of an anti-EGFR treatment with cetuximab (including tumour biopsies and liquid biopsies from blood samples) up to 48 months
Secondary Prospective Analysis of Tumour Marker Level Evolution (CEA and CA 19-9) Investigation of prospective analysis of tumour marker level evolution (CEA and CA 19-9) up to 48 months
Secondary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Recording of the safety and tolerability (NCI-CTCAE version 4.03 criteria) of the treatment up to 48 months
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphereâ„¢ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2